Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)
ID: 356925Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356925

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-211.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)" aimed at supporting innovative mechanistic research to develop precision probiotic interventions. This initiative seeks to identify person-specific biological features that influence probiotic responses, thereby enhancing clinical outcomes and addressing the variability in individual responses to probiotics. The funding, which can reach a maximum of $350,000 annually over a combined duration of up to five years, is open to a diverse range of applicants, including educational institutions and nonprofit organizations, while excluding foreign entities. Interested applicants must submit their proposals by June 2, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-211-Full-Announcement.html
    PAR-25-211.html
    The Department of Health and Human Services announces a funding opportunity for innovative mechanistic research aimed at developing precision probiotic therapies, governed by a biphasic R61/R33 award mechanism. The goal is to address the variability in individual responses to probiotics due to biological and environmental factors. The R61 phase will support studies identifying host biological patterns linked to probiotic effects, while the subsequent R33 phase will further investigate these relationships using rigorous mechanistic designs in either animal models or human subjects. A transition from R61 to R33 requires review and is contingent on specific milestones being met. Funding is set at a maximum of $350,000 annually over a combined duration of up to five years. Eligible applicants include various educational institutions, nonprofit organizations, and governmental entities, but foreign organizations are excluded. An important aspect of this funding includes a requirement for a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity during the research process. The review of applications will emphasize scientific merit, innovation, rigor, and the impact of the proposed projects. This initiative exemplifies the NIH's commitment to advancing personalized health approaches in the domain of complementary and integrative health studies.
    Similar Opportunities
    Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)." This initiative aims to support innovative mechanistic research that addresses the variability in individual responses to probiotics, with the goal of developing effective interventions tailored to person-specific biological features. The funding mechanism employs a biphasic approach, where the R61 phase focuses on identifying host biological patterns correlated with probiotic effects through observational studies, and the R33 phase rigorously tests causality in animal or human studies, with a total budget not exceeding $350,000 per year for both phases. Interested applicants must submit their proposals by June 2, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)" aimed at advancing innovative research into precision probiotic interventions. This initiative seeks applications that will investigate person-specific factors influencing probiotic responses, such as microbiome composition, age, sex, genetic background, and lifestyle, to identify subgroups that may benefit from tailored probiotic treatments. The funding is crucial for addressing variability in human responses to probiotics and aims to enhance health outcomes through targeted interventions. Applicants can request up to $350,000 per year for a maximum of four years, with the application deadline set for June 2, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-239.html.
    Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)" aimed at advancing innovative research into the biological factors that influence individual responses to probiotics. This initiative seeks applications that will explore person-specific characteristics, such as genetics, microbiome composition, and lifestyle, to improve the effectiveness of probiotic interventions and address variability in human responses. The total project period is limited to four years, with a maximum budget of $350,000 in direct costs per year, and applications are expected to include a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity. Interested applicants can find more information and submission guidelines at the NIH website, with the application deadline set for June 2, 2027, and anticipated awards starting in June 2025. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)" aimed at supporting mid-phase clinical trials of natural products, including botanicals, dietary supplements, and probiotics, that demonstrate promising preliminary evidence for health benefits. Applicants are required to provide sufficient preliminary data, adhere to FDA regulations, and develop a Plan for Enhancing Diverse Perspectives (PEDP) to foster inclusivity in research, with a focus on determining optimal dosing and patient responsiveness before advancing to larger efficacy trials. This funding opportunity is critical for addressing knowledge gaps in complementary health approaches, particularly in symptom management and health disparities. The estimated total program funding is $350,000, with applications due by November 13, 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), invites applications for the NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33), aimed at supporting early-phase clinical trials of natural products such as botanicals and dietary supplements. This funding opportunity encourages research that evaluates the pharmacokinetics, safety, and efficacy of these natural products, with a focus on advancing promising interventions backed by prior scientific evidence. The program is designed to foster innovative clinical research that enhances understanding of the beneficial impacts of natural products on health conditions, while ensuring inclusivity through a Plan for Enhancing Diverse Perspectives (PEDP). Applicants may request up to $350,000 per year, with a project duration of up to six years contingent upon successful milestone completion, and the application deadline is November 13, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer," aimed at supporting exploratory research into the human microbiome's role in anti-tumor immunity. This initiative seeks to elucidate the mechanisms by which specific microbes or their metabolites influence immune responses and inflammation related to tumor formation, with a focus on identifying novel molecular targets for cancer prevention strategies. Eligible applicants include a wide range of organizations, such as educational institutions, nonprofits, and tribal governments, with funding available up to $275,000 for two-year projects. Interested parties should submit their applications by January 7, 2025, and can find additional information at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCCIH Natural Product Early Phase Clinical Trial Award (R33), aimed at funding early phase clinical trials focused on natural products such as botanicals and dietary supplements. This funding opportunity encourages research that rigorously evaluates the effects of these products on specific biological targets, with a total budget limit of $1,050,000 in direct costs available for up to three years of support. The initiative is particularly relevant for addressing health issues like chronic pain and gastrointestinal disorders, emphasizing the importance of diverse research collaborations and methodologies. Interested applicants must comply with NIH grants policies and submit their proposals by November 13, 2026, while also enhancing research diversity through a Plan for Enhancing Diverse Perspectives (PEDP). For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer," aimed at supporting basic research into the human microbiome's role in anti-tumor immune responses. Applicants are required to develop innovative projects that explore the interactions between specific microbes or their metabolites and host immune responses, with a focus on identifying mechanisms that may enhance or inhibit tumor formation. This initiative is significant for advancing cancer research and understanding the implications of microbiome interactions in immunology. The funding, administered under the R01 Research Project Grant mechanism, has no budget limit and is open to a diverse range of eligible organizations, with a project duration of up to five years. Interested parties can find more information and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by January 7, 2025.
    NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCCIH Natural Product Early Phase Clinical Trial Award (R33), aimed at supporting investigator-initiated clinical trials of natural products such as botanicals and dietary supplements. This funding opportunity encourages applications for early phase trials that assess the impact of these products on specific biological targets and their potential clinical outcomes, with a focus on optimizing study designs and dosage. The initiative is crucial for advancing research in complementary and integrative health approaches, ensuring that projects adhere to rigorous scientific standards and include a Plan for Enhancing Diverse Perspectives (PEDP). The total estimated funding for this program is $1,050,000, with applications due by November 13, 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information page at https://grants.nih.gov/grants/guide/pa-files/PAR-25-270.html.
    NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), has announced the NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33), aimed at supporting early-phase clinical trials of natural products such as botanicals and dietary supplements. This funding opportunity encourages applications that demonstrate a strong scientific basis for further testing, focusing on pharmacokinetics, bioavailability, and measurable effects on target mechanisms rather than just clinical symptoms. The award consists of two phases: the R61 phase provides up to three years of funding for milestone-driven studies, while the R33 phase may extend funding for an additional three years contingent upon achieving R61 milestones. Interested applicants can find more details and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with a total estimated program funding of $350,000 and a closing date for applications set for November 13, 2026.